Natalia Aptsiauri
Granada, AN 18012, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer.
Journal: Journal for immunotherapy of cancer
Published: September 26, 2024
The Challenges of HLA Class I Loss in Cancer Immunotherapy: Facts and Hopes.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 16, 2022
Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer.
Journal: Pharmaceutics
Published: January 12, 2022
Tumor Escape Phenotype in Bladder Cancer Is Associated with Loss of HLA Class I Expression, T-Cell Exclusion and Stromal Changes.
Journal: International journal of molecular sciences
Published: May 26, 2021
HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy.
Journal: Cellular & molecular immunology
Published: October 15, 2020
Cancer immune escape: MHC expression in primary tumours versus metastases.
Journal: Immunology
Published: June 17, 2019
A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer.
Journal: Annals of surgical oncology
Published: August 21, 2018
HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15.
Journal: Immunogenetics
Published: May 25, 2018
The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses.
Journal: Current opinion in immunology
Published: October 12, 2017
Last Updated: 09/26/2026